Exelixis

Exelixis EBIT per Employee

The EBIT per Employee of Exelixis (EXEL) as of Oct 16, 2026 is 809,833.80 USD. In the previous year, EBIT per Employee was 561,389.97 USD — a change of 44.26% (higher).

EBIT per Employee

809,833.80USD

YoY

44.26%

Last updated:

EBIT per Employee of Exelixis is 2025 809,833.80 USD. EBIT per Employee of Exelixis was 2024 561,389.97 USD. It decreases by 44.26% higher compared to the previous year.

The Exelixis EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
407,479.11 USD
Jan 1, 2019
343,054.78 USD
Jan 1, 2020
102,191.27 USD
Jan 1, 2021
266,170.84 USD
Jan 1, 2022
187,078.92 USD
Jan 1, 2023
158,667.60 USD
Jan 1, 2024
561,389.97 USD
Jan 1, 2025
809,833.80 USD
The Exelixis EBIT per Employee history
YEAREBIT per EmployeeYoY
809,833.80USD+44.26%
561,389.97USD+253.82%
158,667.60USD-15.19%
187,078.92USD-29.71%
266,170.84USD+160.46%
102,191.27USD-70.21%
343,054.78USD-15.81%
407,479.11USD+164.51%
154,048.28USD-689.92%
-26,113.28USD-76.84%
-112,740.02USD-45.90%
-208,410.40USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exelixis stock

EBIT per Employee of Exelixis is 809,833.80 USD in 2025.

EBIT per Employee of Exelixis changed from 561,389.97 USD to 809,833.80 USD, representing a 44.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee Exelixis since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's Exelixis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — Exelixis

All Key Metrics — Exelixis